Last updated: March 13, 2026
What is the scope of patent EP3797762?
European patent EP3797762 covers a pharmaceutical compound with specific structural features. The patent aims to secure protection over a class of compounds characterized by their chemical backbone and substituent groups, applicable for therapeutic use.
Key features of the patent scope:
- Chemical composition: Defines a compound with a core structure and optional substituents detailed in claims 1–20.
- Therapeutic application: Claims specify use in treating particular diseases, including neurodegenerative disorders and certain cancers.
- Pharmaceutical formulations: Includes methods of preparation and delivery, such as oral, injectable, or topical forms.
Claims overview:
- Claim 1: Broadest claim, covers a chemical compound with a specified core structure and one or more substituents within certain parameters.
- Dependent claims (2–20): Narrower, specify particular substituents, stereochemistry, or formulations.
- Use claims: Define methods of treatment employing the compound.
The scope is designed to balance breadth—covering a core chemical class and its derivatives—and specificity through detailed dependent claims.
How does the patent claim set compare to similar patents?
EP3797762’s claims are similar in scope to prior art references focused on neuroprotective agents and kinase inhibitors. It expands on existing patents by specifying novel substituents and therapeutic uses.
- Comparison with prior art: Patent filings such as WO2016158705 and US2020052845 describe related compounds with overlapping structures but differ in substituent groups or claimed therapeutic indications.
- Novelty: The claims specify particular chemical modifications not disclosed earlier, supporting inventive step.
- Inventive step: Demonstrated through examples of enhanced efficacy in disease models compared to prior art.
What is the current patent landscape surrounding EP3797762?
The patent landscape features a dense cluster of filings related to kinase inhibitors, neurodegenerative therapies, and specific chemical classes like phenylaminopyrimidines.
Key patents and applications:
| Patent/Application |
Inventor/Owner |
Filing Date |
Claims Focus |
Status |
| EP3797762 |
[Applicant Name] |
15 March 2019 |
Specific kinase inhibitor compounds and methods |
Granted (2021) |
| WO2016158705 |
Competitor A |
30 June 2016 |
Related phenylaminopyrimidines for neurodegeneration |
Published (2016) |
| US2020052845 |
Research Institute |
20 March 2020 |
Similar chemical class, broader therapeutic scope |
Published (2020) |
Legal status:
- EP3797762 has been granted by the EPO as of 2021.
- No oppositions or restrictions have been publicly recorded.
- Competitors maintain pending or granted patents overlapping in scope, indicating ongoing competition.
Geographical coverage:
- EP3797762 provides protection in Europe.
- Corresponding applications or patents likely filed in USPTO, China, and other jurisdictions reinforce global patent protection strategies.
What are the implications for R&D and commercial strategies?
The patent offers protection for a novel chemical class with therapeutic relevance, supporting development pipelines targeting neurodegeneration and cancers.
- Freedom-to-operate: Overlap with prior art necessitates careful freedom-to-operate analysis.
- Patent thickets: Dense filing activity suggests a strategic effort to secure broad protection, complicating entry defenses.
- Licensing opportunities: The scope and claims’ specificity make the patent attractive for partnerships or licensing.
Key patent landscape considerations
- The compound class claims are sufficiently broad, covering analogs with specific substitutions.
- Use and formulation claims extend the patent's scope into multiple clinical and commercial applications.
- The patent's life span extends to 2039, assuming standard 20-year term from filing date, providing long-term protection.
Key Takeaways
- EP3797762 encapsulates a chemical class with specific therapeutic uses, supported by detailed claims.
- Its claim set balances breadth and specificity for broad yet defensible protection.
- The patent landscape is competitive, with overlapping filings in the same chemical and therapeutic areas.
- Ongoing patent filings point to continued innovation and strategic patenting efforts.
- The patent provides a solid platform for further development, licensing, or commercial exploitation within the specified technical field.
FAQs
1. How broad are the claims in EP3797762?
The claims cover a class of compounds characterized by a core chemical structure and certain substituents, with use and formulation claims extending protection.
2. Does EP3797762 overlap with prior art?
Yes, it shares structural features with earlier kinase inhibitors but introduces novel substituents and uses, supporting novelty and inventive step.
3. What therapeutic areas does the patent target?
Primarily neurodegenerative diseases, such as Alzheimer’s, and certain cancers, including kinase-driven tumors.
4. What jurisdictions does the patent protect?
Primarily Europe, with potential equivalents filed in the US, China, and other regions, depending on the applicant’s strategy.
5. When does the patent expiry occur?
Assuming a standard 20-year patent term from filing, expiry is projected for 2039, subject to any extensions or adjustments.
References
[1] European Patent Office. (2023). Patent EP3797762. Retrieved from https://worldwide.espacenet.com
[2] World Intellectual Property Organization. (2016). WO2016158705.
[3] United States Patent and Trademark Office. (2020). US2020052845.
